Literature DB >> 15799553

Inter-evaluator reliability of the ALS functional rating scale.

Barbara Miano1, Gregory J Stoddard, Summer Davis, Mark B Bromberg.   

Abstract

The ALS Functional Rating Scale-Revised (ALSFRS-R) is used in the clinic to chart progression and as a primary endpoint measure in clinical trials. In the original description of the scale, evaluations were to be performed by the patient or caregiver, but ratings are commonly performed by health care providers. We determined whether there are differences in scoring based on whether the provider, patient or caregiver performed the evaluation. Overall, all evaluators assessed similar changes in function over time, but significant visit-specific differences were found with higher scores when the patient and provider were the evaluators. We modeled how a change in evaluators at the end of a 9-month trial would influence statistical analysis, if the patient was unable to travel to the study site and the final assessment was performed by telephone. If 25% of the final visit assessments were performed by the patient, in place of the provider, the change in score is less than one point on the ALSFRS-R (-0.7: 95% Confidence Interval -2.1 to 0.3). We conclude that the ALSFRS-R can be successfully used even if evaluators change.

Entities:  

Mesh:

Year:  2004        PMID: 15799553     DOI: 10.1080/14660820410021302

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord        ISSN: 1466-0822


  15 in total

Review 1.  Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis.

Authors:  Seward B Rutkove
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

2.  Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.

Authors:  Swati P Aggarwal; Lorne Zinman; Elizabeth Simpson; Jane McKinley; Katherine E Jackson; Hanika Pinto; Petra Kaufman; Robin A Conwit; David Schoenfeld; Jeremy Shefner; Merit Cudkowicz
Journal:  Lancet Neurol       Date:  2010-04-01       Impact factor: 44.182

3.  Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy.

Authors:  Jessica Mandrioli; Sara Biguzzi; Carlo Guidi; Elisabetta Sette; Emilio Terlizzi; Alessandro Ravasio; Mario Casmiro; Fabrizio Salvi; Rocco Liguori; Romana Rizzi; Vladimiro Pietrini; Annamaria Borghi; Rita Rinaldi; Nicola Fini; Elisabetta Chierici; Mario Santangelo; Enrico Granieri; Vittoria Mussuto; Silvia De Pasqua; Eleni Georgoulopoulou; Antonio Fasano; Salvatore Ferro; Roberto D'Alessandro
Journal:  Neurol Sci       Date:  2015-07-24       Impact factor: 3.307

Review 4.  Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design.

Authors:  Christina N Fournier
Journal:  Neurotherapeutics       Date:  2022-07-11       Impact factor: 6.088

5.  Validation of the German version of the extended ALS functional rating scale as a patient-reported outcome measure.

Authors:  Susanne Abdulla; Stefan Vielhaber; Sonja Körner; Judith Machts; Hans-Jochen Heinze; Reinhard Dengler; Susanne Petri
Journal:  J Neurol       Date:  2013-06-05       Impact factor: 4.849

6.  Online assessment of ALS functional rating scale compares well to in-clinic evaluation: a prospective trial.

Authors:  André Maier; Teresa Holm; Paul Wicks; Laura Steinfurth; Peter Linke; Christoph Münch; Robert Meyer; Thomas Meyer
Journal:  Amyotroph Lateral Scler       Date:  2012-02

7.  Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model.

Authors:  Leonhard A Bakker; Carin D Schröder; Michael A van Es; Paul Westers; Johanna M A Visser-Meily; Leonard H van den Berg
Journal:  J Neurol       Date:  2017-06-12       Impact factor: 4.849

8.  Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS.

Authors:  Michael Benatar; Joanne Wuu; Peter M Andersen; Nazem Atassi; William David; Merit Cudkowicz; David Schoenfeld
Journal:  Neurology       Date:  2018-01-24       Impact factor: 9.910

9.  Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysis.

Authors:  Jordan R Green; Kristen M Allison; Claire Cordella; Brian D Richburg; Gary L Pattee; James D Berry; Eric A Macklin; Erik P Pioro; Richard A Smith
Journal:  Br J Clin Pharmacol       Date:  2018-10-01       Impact factor: 4.335

10.  Bulbar and speech motor assessment in ALS: challenges and future directions.

Authors:  Jordan R Green; Yana Yunusova; Mili S Kuruvilla; Jun Wang; Gary L Pattee; Lori Synhorst; Lorne Zinman; James D Berry
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2013-07-30       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.